Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy

Clinical Infectious Diseases

Volumn 46, Issue 2, 2008, Pages 305-312

  Golub, Elizabeth T ^a   Benning, Lorie ^a   Sharma, Anjali ^b   Gandhi, Monica ^c   Cohen, Mardge H ^d   Young, Mary ^e   Gange, Stephen J ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d RUSH MEDICAL COLLEGE   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR;

ADULT; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL EXAMINATION; CONTROLLED STUDY; DRUG SUBSTITUTION; ETHNICITY; FEMALE; HEALTH INSURANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LANGUAGE; LINEAR REGRESSION ANALYSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; VEIN PUNCTURE; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 39449111609     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/524752     Document Type: Article

References (30)

1. d'Arminio MA, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS 2000; 14:499-507.
2. Yan Q, Hruz PW. Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal. J Acquir Immune Defic Syndr 2005; 40:398-403.
3. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13:F63-70.
4. Justman JE, Benning L, Danoff A, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003; 32:298-302.
5. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
6. Zareba KM, Miller TL, Lipshultz SE. Cardiovascular disease and toxicities related to HIV infection and its therapies. Expert Opin Drug Saf 2005; 4:1017-25.
7. Grunfeld C, Tien P. Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome. Clin Infect Dis 2003; 37:S43-6.
8. Nolan D. Metabolic complications associated with HIV protease inhibitor therapy. Drugs 2003; 63:2555-74.
9. Wohl DA, McComsey G, Tebas P, et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 2006; 43:645-53.
10. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005; 40:158-63.
11. van Roon EN, Verzijl JM, Juttmann JR, Lenderink AW, Blans MJ, Egberts AC. Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:290-4.
12. Le Moing V, Chene G, Leport C, et al. Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients. Clin Infect Dis 2002; 34:239-47.
13. Dorrucci M, Pezzotti P, Grisorio B, et al. Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens. AIDS 2001; 15:1733-6.
14. Mocroft A, Youle M, Moore A, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001; 15:185-94.
15. Kirstein LM, Greenblatt RM, Anastos K, et al. Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2002; 29:495-503.
16. Dieleman JP, Sturkenboom MC, Wit FW, et al. Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression. J Infect Dis 2002; 185:1261-8.
17. Bucher HC, Kofler A, Nuesch R, Young J, Battegay M, Opravil M. Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients. AIDS 2003; 17:2451-9.
18. Maggiolo F, Ripamonti D, Ravasio L, et al. Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection. Clin Infect Dis 2003; 37:41-9.
19. Maggiolo F, Ripamonti D, Suter F. Switch strategies in patients on effective HAART. J Antimicrob Chemother 2005; 55:821-3.
20. Mocroft A, Phillips AN, Ledergerber B, et al. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS 2006; 20:1141-50.
21. Abgrall S, Yeni PG, Bouchaud O, Costagliola D. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir. Clin Infect Dis 2007; 44:120-7.
22. Mocroft A, Horban A, Clumeck N, et al. Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naive patients starting cART after January 1, 2000. HIV Clin Trials 2006; 7:271-84.
23. Pulido F, Arribas JR, Miro JM, et al. Clinical, virologic, and immunologic response to efavirenz- or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study). J Acquir Immune Defic Syndr 2004; 35:343-50.
24. Waters L, Stebbing J, Jones R, et al. A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts. J Antimicrob Chemother 2004; 54:503-7.
25. Bacon MC, von Wyl V, Alden C, et al. The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol 2005; 12:1013-9.
26. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 1998; 9:117-25.
27. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley, 1989.
28. Singer JD, Willett JB. Applied longitudinal data analysis: modeling change and event occurrence. New York: Oxford University Press, 2003.
29. Anderson AM, Bartlett JA. Changing antiretroviral therapy in the setting of virologic relapse: review of the current literature. Curr HIV/ AIDS Rep 2006; 3:79-85.
30. MacArthur RD, Novak RM, Peng G, et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet 2006; 368:2125-35.